Earnings Call · Q4 FY2022·2023-02-23

Q4 22EPS -20.00%·Rev n/aQ3 22EPS +3.85%·Rev n/aQ2 22EPS -64.29%·Rev n/aQ1 22EPS +77.78%·Rev n/a⚠ consensus missing

NovoCure Ltd NVCR

Ingrid Goldberg — Investor Relations

William Doyle — Executive Chairman

Asaf Danziger — Chief Executive Officer

Ashley Cordova — Chief Financial Officer

−16.3%1d on move date−16.3% vs SPY3d−11.3%5d−13.8%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NVCR calls or request research access.

More NVCR calls Browse calls Request research access